Septal Reduction Using Transvenous Intramyocardial Cerclage Radiofrequency Ablation: Preclinical Feasibility.

Debulking of left ventricular septal mass is typically accomplished using surgical myectomy, which is morbid, or using transcoronary alcohol septal ablation, which can result in geographic miss and occasional catastrophic nontarget coronary injury. The authors developed and tested operational parameters in vitro and vivo for a device to accomplish transvenous intraseptal radiofrequency ablation to reduce ventricular septal mass using a technique derived from mitral cerclage, which the authors call cerclage ablation . Cerclage ablation appeared feasible in vitro and safe and effective in vivo. Cerclage ablation is an attractive new approach to debulk the interventricular septum in obstructive hypertrophic cardiomyopathy. These data support clinical investigation.
Competing Interests: This study was supported by Research and Development grant S2773417 from the Korean Ministry of Small and Medium Enterprise and Startups. Tau-PNU Medical provided the prototype ablation catheters. Dr. J.-W. Park is a medical consultant for Tau-PNU Medical. Drs. J.-H. Kim and Nam are coinventors on patents for devices for mitral loop cerclage ablation. Dr. J.-H Kim is a stockholder of Tau-PNU Medical. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
(© 2020 The Authors.)